Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 4/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Diniprofylline SCHEMBL30035984 | 1.00 | LMNA (0.55) | LMNAGAASMN1; SMN2RXFP1POLB | |
| SCHEMBL10970100 | 0.89 | LMNA (0.64) | LMNAGAASMN1; SMN2RXFP1POLB | |
| SCHEMBL11389921 | 0.85 | LMNA (0.57) | LMNAGAASMN1; SMN2RXFP1ALDH1A1 | |
| Etofylline Nicotinate SCHEMBL1649975 | 0.84 | ADORA2B (0.64) | LMNAGAASMN1; SMN2RXFP1ALDH1A1 | |
| SCHEMBL10970102 | 0.82 | LMNA (0.56) | LMNAGAASMN1; SMN2RXFP1POLB | |
| SCHEMBL25295543 | 0.79 | LMNA (0.56) | LMNAGAASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL30563571 | 0.79 | LMNA (0.56) | LMNAGAASMN1; SMN2RXFP1ADORA2B | |
| SCHEMBL11389732 | 0.77 | PDE1A (0.55) | LMNAGAASMN1; SMN2RXFP1ALDH1A1 | |
| Etofylline SCHEMBL27405019 | 0.77 | LMNA (0.70) | LMNAGAASMN1; SMN2RXFP1POLB | |
| SCHEMBL11377360 | 0.76 | LMNA (0.59) | LMNAGAASMN1; SMN2RXFP1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 87 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| CN-101330905-A | Freeze-drying process and products obtained thereby | SCIDOSE LLC (US) | 2008-12-24 | — | — | CN | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1771022-A | Cosmetic composition containing a fatty acid glyceride, an alcohol and a silicone emulsifier | OREAL (FR) | 2006-05-10 | — | — | CN | claimed |
| US-12472186-B2 | Pharmaceutical compositions and methods of treating cardiovascular diseases | Cardix Therapeutics LLC (US) | 2025-11-18 | — | — | US | disclosed |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | ANSELLA THERAPEUTICS INC (US) | 2025-11-13 | — | — | US | disclosed |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | Ansella Therapeutics, Inc. (US) | 2025-01-21 | — | — | US | disclosed |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-08-29 | — | — | US | disclosed |
| US-20240207279-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | Cardix Therapeutics LLC (US) | 2024-06-27 | — | — | US | disclosed |
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | CARDIX Therapeutics, LLC (US) | 2024-04-09 | — | — | US | disclosed |
| US-6680047-B2 | FOR USE IN ULTRASOUND IMAGING, CONTRAST AGENTS | AMERSHAM HEALTH AS (NO) | 2004-01-20 | — | — | US | disclosed |
| US-20020102215-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-20020102217-A1 | Diagnostic/therapeutic agents | NYCOMED IMAGING AS | 2002-08-01 | — | — | US | disclosed |
| US-6331289-B1 | ULTRASOUND CONTRAST AGENTS, SUSPENSION IN AQUEOUS CARRIER LIQUID OF A REPORTER COMPRISING GAS-CONTAINING OR GAS-GENERATING MATERIAL, AGENT CAPABLE OF FORMING AT LEAST TWO TYPES OF BINDING PAIRS WITH TARGET; REPORTER BEING CONJUGATED | NYCOMED IMAGING AS (NO) | 2001-12-18 | — | — | US | disclosed |
| US-6264917-B1 | MIXTURE OF GAS FILLED MICROBUBBLES AND RELEASING AGENT | NYCOMED IMAGING AS (NO) | 2001-07-24 | — | — | US | disclosed |
| US-6261537-B1 | TARGETS AND ULTRASOUND DIAGNOSIS OF ACTIVE MATERIALS, AQUEOUS CARRIER LIQUIDS, CARRIERS AND FILM FORMING SURFACTANT PHOSPHATIDES | NYCOMED IMAGING AS (NO) | 2001-07-17 | — | — | US | disclosed |
| EP-0390612-A1 | Drug production using non-cross reactive antibodies | SYNBIOTICS CORPORATION (US) | 1990-10-03 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11951107-B2 | Deuterated pharmaceutical compositions and methods of treating cardiovascular diseases | ADRB2, ADRA2C, ADRB1 | LMNA 1687/4885GAA 1649/4885SMN1; SMN2 2580/4885 |
| US-20240285639-A1 | DEUTERATED PHARMACEUTICAL COMPOSITIONS AND METHODS OF TREATING CARDIOVASCULAR DISEASES | ADRB2, ADRA2C, ADRB1 | LMNA 1687/4885GAA 1649/4885SMN1; SMN2 2580/4885 |
| US-12201607-B2 | Compositions and methods for preventing and treating conditions | LIPA, COL2A1, COL1A1 | LMNA 43/4885GAA 49/4885SMN1; SMN2 93/4885 |
| US-20250345308-A1 | COMPOSITIONS AND METHODS FOR PREVENTING AND TREATING CONDITIONS | LIPA, COL2A1, COL1A1 | LMNA 43/4885GAA 49/4885SMN1; SMN2 93/4885 |
| US-20020102215-A1 | Diagnostic/therapeutic agents | BID, FUS, FABP1 | LMNA 1552/4885GAA 2444/4885SMN1; SMN2 1978/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.